On improvement in ejection fraction with iron chelation in thalassemia major and the risk of future heart failure

Journal of Cardiovascular Magnetic Resonance

Volumn 13, Issue 1, 2011, Pages

  Pennell, D J ^a,b   Carpenter, J P ^a,b   Roughton, M ^c   Cabantchik, Z I ^d  

^a ROYAL BROMPTON HOSPITAL   (United Kingdom)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d HEBREW UNIVERSITY OF JERUSALEM   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON CHELATING AGENT;

ADULT; ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IRON CHELATION; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION; SIDEROSIS; THALASSEMIA MAJOR; TREATMENT OUTCOME; UNITED KINGDOM; ADOLESCENT; BETA THALASSEMIA; CARDIOMYOPATHY; CONVALESCENCE; DRUG EFFECT; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; RISK ASSESSMENT; RISK FACTOR; TIME;

ADOLESCENT; ADULT; BETA-THALASSEMIA; CARDIOMYOPATHIES; FEMALE; GREAT BRITAIN; HEART FAILURE; HUMANS; IRON CHELATING AGENTS; MAGNETIC RESONANCE IMAGING; MALE; RECOVERY OF FUNCTION; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; TIME FACTORS; TREATMENT OUTCOME; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT; YOUNG ADULT;

EID: 84855169923     PISSN: 10976647     EISSN: 1532429X     Source Type: Journal    
DOI: 10.1186/1532-429X-13-45     Document Type: Article

References (82)

1. Cardiovascular T2-star (T2*) magnetic resonance for the early diagnosis of myocardial iron overload. Anderson LJ, Holden S, Davis B, Prescott E, Charrier CC, Bunce NH, Firmin DN, Wonke B, Porter J, Walker JM, Pennell DJ, Eur Heart J 2001 23 2171 9 (Pubitemid 33139463)
2. On T2* magnetic resonance and cardiac iron. Carpenter JP, He T, Kirk P, Roughton M, Anderson LJ, de Noronha SV, Sheppard MN, Porter JB, Walker JM, Wood JC, Galanello R, Forni G, Catani G, Matta G, Fucharoen S, Fleming A, House MJ, Black G, Firmin DN, St Pierre TG, Pennell DJ, Circulation 2011 123 1519 28 10.1161/CIRCULATIONAHA.110.007641 21444881
3. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Nair SV, Anderson LJ, Walker JM, Pennell DJ, J Cardiovasc Magn Reson 2006 8 543 7 10.1080/10976640600698155 16755844
4. T2* cardiovascular magnetic resonance in the management of thalassemia patients in Oman. Daar S, Pathare AV, Jain R, Zadjali SA, Pennell DJ, Haematologica 2009 94 140 1 10.3324/haematol.13845 19001285
5. Myocardial iron loading in patients with thalassemia major on deferoxamine chelation. Tanner MA, Galanello R, Dessi C, Westwood MA, Smith GC, Nair SV, Anderson LJ, Walker JM, Pennell DJ, J Cardiovasc Magn Reson 2006 8 543 7 10.1080/10976640600698155 16755844
6. Cardiac magnetic resonance in transfusion dependent thalassaemia: assessment of iron load and relationship to left ventricular ejection fraction. Chouliaras GL, Kattamis A, Berdoukas V, Gotsis ED, Mavrogeni S, Ladis V, Br J Haematol 2010 151 397 401 10.1111/j.1365-2141.2010.08365.x 20813008
7. Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* magnetic resonance imaging study. Marsella M, Borgna-Pignatti C, Meloni A, Caldarelli V, Dell'Amico MC, Spasiano A, Pitrolo L, Cracolici E, Valeri G, Positano V, Lombardi M, Pepe A, Haematologica 2011 96 515 20 10.3324/haematol.2010.025510 21228034
8. Randomized controlled trial of deferiprone or deferoxamine in beta-thalassemia major patients with asymptomatic myocardial siderosis. Pennell DJ, Berdoukas V, Karagiorga M, Ladis V, Piga A, Aessopos A, Gotsis ED, Tanner MA, Smith GC, Westwood MA, Wonke B, Galanello R, Blood 2006 107 3738 44 10.1182/blood-2005-07-2948 16352815
9. A randomized, placebo controlled, double blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ, Circulation 2007 115 1876 84 10.1161/CIRCULATIONAHA.106. 648790 17372174 (Pubitemid 46598901)
10. Combined chelation therapy in thalassemia major for the treatment of severe myocardial siderosis with left ventricular dysfunction. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Pibiri M, Nair SV, Walker JM, Pennell DJ, J Cardiovasc Magn Reson 2008 10 12 10.1186/1532-429X-10-12 18298856
11. Efficacy of deferasirox in reducing and preventing cardiac iron overload in beta-thalassemia. Pennell DJ, Porter JB, Cappellini MD, El-Beshlawy A, Chan LL, Aydinok Y, Elalfy MS, Sutcharitchan P, Li CK, Ibrahim H, Viprakasit V, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A, Blood 2010 115 2364 71 10.1182/blood-2009-04-217455 19996412
12. The efficacy of iron chelator regimes in reducing cardiac and hepatic iron in patients with thalassaemia major: a clinical observational study. Berdoukas V, Chouliaras G, Moraitis P, Zannikos P, Berdoussi E, Ladis V, J Cardiovasc Magn Reson 2009 11 20 10.1186/1532-429X-11-20 19558722
13. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A, Blood 2006 107 3733 7 10.1182/blood-2005-07-2933 16373663
14. Improved survival of thalassaemia major in the UK and relation to T2* cardiovascular magnetic resonance. Modell B, Khan M, Darlison M, Westwood MA, Ingram D, Pennell DJ, J Cardiovasc Magn Reson 2008 10 42 10.1186/1532-429X-10-42 18817553
15. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A, Angastiniotis M, Haematologica 2009 94 1777 8 10.3324/haematol.2009. 009118 19815834
16. Myocardial iron clearance during reversal of siderotic cardiomyopathy with intravenous desferrioxamine: a prospective study using T2* cardiovascular magnetic resonance. Anderson LJ, Westwood MA, Holden S, Davis B, Prescott E, Wonke B, Porter JB, Walker JM, Pennell DJ, Br J Haematol 2004 127 348 55 10.1111/j.1365-2141.2004.05202.x 15491298 (Pubitemid 39468951)
17. Heart failure in beta thalassemia: a 5-year follow-up study. Kremastinos DT, Tsetsos GA, Tsiapras DP, Karavolias GK, Ladis VA, Kattamis CA, Am J Med 2001 111 407 8 10.1016/S0002-9343(01)00943-3 11583647 (Pubitemid 32913677)
18. Cardiac T2* magnetic resonance for prediction of cardiac complications in thalassemia major. Kirk P, Roughton M, Porter JB, Walker JM, Tanner MA, Patel J, Wu D, Taylor J, Westwood MA, Anderson LJ, Pennell DJ, Circulation 2009 120 1961 8 10.1161/CIRCULATIONAHA.109.874487 19801505
19. Normalized left ventricular volumes and function in thalassemia major patients with normal myocardial iron. Westwood MA, Anderson LJ, Maceira AM, Shah FT, Prescott E, Porter JB, Wonke B, Walker JM, Pennell DJ, J Magn Reson Imaging 2007 25 1147 51 10.1002/jmri.20915 17520718 (Pubitemid 46870271)
20. A single breath-hold multiecho T2* cardiovascular magnetic resonance technique for diagnosis of myocardial iron overload. Westwood M, Anderson LJ, Firmin DN, Gatehouse PD, Charrier CC, Wonke B, Pennell DJ, J Magn Reson Imaging 2003 18 33 9 10.1002/jmri.10332 12815637 (Pubitemid 36791266)
21. Normalized left ventricular systolic and diastolic function by steady state free precession cardiovascular magnetic resonance. Maceira AM, Prasad SK, Khan M, Pennell DJ, J Cardiovasc Magn Reson 2006 8 417 26 10.1080/ 10976640600572889 16755827
22. Comparison of interstudy reproducibility of cardiovascular magnetic resonance with two-dimensional echocardiography in normal subjects and in patients with heart failure or left ventricular hypertrophy. Grothues F, Smith GC, Moon JCC, Bellenger NG, Collins P, Klein H, Pennell DJ, Am J Cardiol 2002 90 29 34 10.1016/S0002-9149(02)02381-0 12088775 (Pubitemid 34671198)
23. Assessment of cardiac function. Maceira AM, Bellenger NG, Pennell DJ, Cardiovascular magnetic resonance Churchill Livingstone, Philadelphia, USA, Manning WJ, Pennell DJ, 2 2010
24. Comparative effects of deferiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. Piga A, Gaglioti C, Fogliacco E, Tricta F, Haematologica 2003 88 489 96 12745268 (Pubitemid 36648438)
25. Cardiac morbidity and mortality in deferoxamine- or deferiprone-treated patients with thalassemia major. Borgna-Pignatti C, Cappellini MD, De Stefano P, Del Vecchio GC, Forni GL, Gamberini MR, Ghilardi R, Piga A, Romeo MA, Zhao H, Cnaan A, Blood 2006 107 3733 7 10.1182/blood-2005-07-2933 16373663
26. Risk factors for death in patients with beta-thalassemia major: results of a case-control study. Ceci A, Baiardi P, Catapano M, Felisi M, Cianciulli P, De Sanctis V, Del Vecchio GC, Magnano C, Meo A, Maggio A, Haematologica 2006 91 1420 1 16963395 (Pubitemid 44569822)
27. Improved survival in thalassemia major patients on switching from desferrioxamine to combined chelation therapy with desferrioxamine and deferiprone. Telfer PT, Warburton F, Christou S, Hadjigavriel M, Sitarou M, Kolnagou A, Angastiniotis M, Haematologica 2009 94 1777 8 10.3324/haematol.2009. 009118 19815834
28. Improving survival with deferiprone treatment in patients with thalassemia major: a prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies. Maggio A, Vitrano A, Capra M, Cuccia L, Gagliardotto F, Filosa A, Magnano C, Rizzo M, Caruso V, Gerardi C, Argento C, Campisi S, Cantella F, Commendatore F, D'Ascola DG, Fidone C, Ciancio A, Galati MC, Giuffrida G, Cingari R, Giugno G, Lombardo T, Prossomariti L, Malizia R, Meo A, Roccamo G, Romeo MA, Violi P, Cianciulli P, Rigano P, Blood Cells Mol Dis 2009 42 247 51 10.1016/j.bcmd.2009.01.002 19233692
29. Comparison of effects of oral deferiprone and subcutaneous desferrioxamine on myocardial iron concentrations and ventricular function in beta-thalassaemia. Anderson LJ, Wonke B, Prescott E, Holden S, Walker JM, Pennell DJ, Lancet 2002 360 516 20 10.1016/S0140-6736(02)09740-4 12241655 (Pubitemid 35232104)
30. Value of sequential monitoring of left ventricular ejection fraction in the management of thalassemia major. Davis BA, O'Sullivan C, Jarritt PH, Porter JB, Blood 2004 104 263 9 10.1182/blood-2003-08-2841 15001468 (Pubitemid 38879867)
31. Comparison of left ventricular ejection fraction and volumes in heart failure by echocardiography, radionuclide ventriculography and cardiovascular magnetic resonance Are they interchangeable? Bellenger NG, Burgess MI, Ray SG, Lahiri A, Coats AJ, Pennell DJ, CHRISTMAS Study Steering Committee and Investigators, Eur Heart J 2000 21 1387 96 10.1053/euhj.2000.2011 10952828 (Pubitemid 30599134)
32. Combined therapy with idebenone and deferiprone in patients with Friedreich's ataxia. Velasco-Sánchez D, Aracil A, Montero R, Mas A, Jiménez L, O'Callaghan M, Tondo M, Capdevila A, Blanch J, Artuch R, Pineda M, Cerebellum 2011 10 1 8 10.1007/s12311-010-0212-7 20865357
33. Mitochondrial dysfunction may explain the cardiomyopathy of chronic iron overload. Gao X, Qian M, Campian JL, Marshall J, Zhou Z, Roberts AM, Kang YJ, Prabhu SD, Sun XF, Eaton JW, Free Radic Biol Med 2010 49 401 7 10.1016/j.freeradbiomed.2010.04.033 20450972
34. The energetics of genome complexity. Lane N, Martin W, Nature 2010 467 929 34 10.1038/nature09486 20962839
35. Myocardial substrate metabolism in the normal and failing heart. Stanley WC, Recchia FA, Lopaschuk GD, Physiol Rev 2005 85 1093 129 10.1152/physrev. 00006.2004 15987803 (Pubitemid 40894649)
36. Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. Garnier A, Fortin D, Delomenie C, Momken I, Veksler V, Ventura-Clapier R, J Physiol 2003 551 491 501 10.1113/jphysiol.2003.045104 12824444 (Pubitemid 37121707)
37. Energy status of the rapidly paced canine myocardium in congestive heart failure. Montgomery C, Hamilton N, Ianuzzo CD, J Appl Physiol 1992 73 2363 7 1490944 (Pubitemid 23019640)
38. 31P magnetic resonance spectroscopy in dilated cardiomyopathy and coronary artery disease. Altered cardiac high-energy phosphate metabolism in heart failure. Neubauer S, Krahe T, Schindler R, Horn M, Hillenbrand H, Entzeroth C, et al. Circulation 1992 86 1810 8 1451253
39. Bioenergetic abnormalities associated with severe left ventricular hypertrophy. Zhang J, Merkle H, Hendrich K, Garwood M, From AH, Ugurbil K, Bache RJ, J Clin Invest 1993 92 993 1003 10.1172/JCI116676 8349829 (Pubitemid 23262424)
40. Functional and bioenergetic modulations in the infarct border zone following autologous mesenchymal stem cell transplantation. Feygin J, Mansoor A, Eckman P, Swingen C, Zhang J, Am J Physiol Heart Circ Physiol 2007 293 1772 80 10.1152/ajpheart.00242.2007 17573463 (Pubitemid 47367227)
41. Decreased energy reserve in an animal model of dilated cardiomyopathy. Relationship to contractile performance. Liao R, Nascimben L, Friedrich J, Gwathmey JK, Ingwall JS, Circ Res 1996 78 893 902 8620610 (Pubitemid 26131374)
42. Myocardial oxygenation during high work states in hearts with postinfarction remodeling. Murakami Y, Zhang Y, Cho YK, Mansoor AM, Chung JK, Chu C, Francis G, Ugurbil K, Bache RJ, From AH, Jerosch-Herold M, Wilke N, Zhang J, Circulation 1999 99 942 8 10027819 (Pubitemid 29094310)
43. 31P NMR spectroscopy detects metabolic abnormalities in asymptomatic patients with hypertrophic cardiomyopathy. Jung WI, Sieverding L, Breuer J, Hoess T, Widmaier S, Schmidt O, Bunse M, van Erckelens F, Apitz J, Lutz O, Dietze GJ, Circulation 1998 97 2536 42 9657474 (Pubitemid 28294500)
44. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. Link G, Saada A, Pinson A, Konijn AM, Hershko C, J Lab Clin Med 1998 131 466 74 10.1016/S0022-2143(98)90148-2 9605112 (Pubitemid 28259763)
45. Pathophysiology of Iron Overload. Hershko C, Link G, Cabantchik ZI, Ann NY Acad Sci 2006 850 191 201
46. Decreased sodium and increased transient outward potassium currents in iron-loaded cardiac myocytes implications for the arrhythmogenesis of human siderotic heart disease. Kuryshev YA, Brittenham GM, Fujioka H, Kannan P, Shieh CC, Cohen SA, Brown AM, Circulation 1999 100 675 83 10441107 (Pubitemid 29379759)
47. Mitochondrial DNA damage in iron overload. Gao X, Campian JL, Qian M, Sun XF, Eaton JW, J Biol Chem 2009 284 4767 75 19095657
48. Mitochondrial dysfunction in cardiac disease: ischemia - reperfusion, aging, and heart failure. Lesnefsky EJ, Moghaddas S, Tandler B, Kerner J, Hoppel CL, J Mol Cell Cardiol 2001 33 1065 89 10.1006/jmcc.2001.1378 11444914 (Pubitemid 32579276)
49. Mitochondrial respiratory enzymes are a major target of iron toxicity in rat heart cells. Link G, Saada A, Pinson A, Konijn AM, Hershko C, J Lab Clin Med 1998 131 466 74 10.1016/S0022-2143(98)90148-2 9605112 (Pubitemid 28259763)
50. ATP and the heart. Ingwall JS, Kluwer Academic Publishers. Norwell, Massachusetts, USA 2002 16 ISBN 1-4020-7093-4
51. The failing heart-an engine out of fuel. Neubauer S, N Engl J Med 2007 356 1140 51 10.1056/NEJMra063052 17360992 (Pubitemid 46425598)
52. Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy. Neubauer S, Horn M, Cramer M, Harre K, Newell JB, Peters W, Pabst T, Ertl G, Hahn D, Ingwall JS, Kochsiek K, Circulation 1997 96 2190 6 9337189 (Pubitemid 27425822)
53. Molecular bases of cellular iron toxicity. Eaton JW, Qian M, Free Radic Biol Med 2002 32 833 40 10.1016/S0891-5849(02)00772-4 11978485 (Pubitemid 34439254)
54. Iron supplementation generates hydroxyl radical in vivo. An ESR spin-trapping investigation. Kadiiska MB, Burkitt MJ, Xiang QH, Mason RP, J Clin Invest 1995 96 1653 7 10.1172/JCI118205 7657835
55. Cardiolipin requirement by cytochrome oxidase and the catalytic role of phospholipid. Fry M, Green DE, Biochem Biophys Res Commun 1980 93 1238 46 10.1016/0006-291X(80)90622-1 6249285
56. Adriamycin inactivates cytochrome c oxidase by exclusion of the enzyme from its cardiolipin essential environment. Goormaghtigh E, Brasseur R, Ruysschaert JM, Biochem Biophys Res Commun 1982 104 314 20 10.1016/0006-291X(82) 91976-3 6280691 (Pubitemid 12146310)
57. Malondialdehyde and 4-hydroxynonenal protein adducts in plasma and liver of rats with iron overload. Houglum K, Filip M, Witztum JL, Chojkier M, J Clin Invest 1990 86 1991 8 10.1172/JCI114934 2123889
58. Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Stadtman ER, Free Radic Biol Med 1990 9 315 25 10.1016/0891-5849(90)90006-5 2283087 (Pubitemid 120036900)
59. Mitochondrial complex I deficiency leads to increased production of superoxide radicals and induction of superoxide dismutase. Pitkanen S, Robinson BH, J Clin Invest 1996 98 345 51 10.1172/JCI118798 8755643 (Pubitemid 26255732)
60. A role for mitochondria in NLRP3 inflammasome activation. Zhou R, Yazdi AS, Menu P, Tschopp J, Nature 2011 469 221 5 10.1038/nature09663 21124315
61. Heart mitochondria: gates of life and death. Gustafsson AB, Gottlieb RA, Cardiovasc Res 2008 77 334 43 18006487 (Pubitemid 351197632)
62. Optical imaging of mitochondrial function uncovers actively propagating waves of mitochondrial membrane potential collapse across intact heart. Lyon AR, Joudrey PJ, Jin D, Nass RD, Aon MA, O'Rourke B, Akar FG, J Mol Cell Cardiol 2010 49 565 75 10.1016/j.yjmcc.2010.07.002 20624394
63. Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial. Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, Paley C, Coates TD, Haematologica 2011 96 1055 8 10.3324/haematol.2010.032862 21393329
64. Cell functions impaired by frataxin deficiency are restored by drug-mediated iron relocation. Kakhlon O, Manning H, Breuer W, Melamed-Book N, Lu C, Cortopassi G, Munnich A, Cabantchik ZI, Blood 2008 112 5219 27 10.1182/blood-2008-06-161919 18796625
65. Deferiprone in the treatment of transfusion-dependent thalassemia: a review and perspective. Galanello R, Ther Clin Risk Manag 2007 3 795 805 18473004 (Pubitemid 350162079)
66. Pharmacokinetics, metabolism, and disposition of deferasirox in beta-thalassemic patients with transfusion-dependent iron overload who are at pharmacokinetic steady state. Waldmeier F, Bruin GJ, Glaenzel U, Hazell K, Sechaud R, Warrington S, Porter JB, Drug Metab Dispos 2010 38 808 16 10.1124/dmd.109.030833 20097723
67. Deferoxamine pharmacokinetics. Porter JB, Semin Hematol 2001 38 Suppl 1 63 8 11206963 (Pubitemid 32110273)
68. Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo. Shalev O, Repka T, Goldfarb A, Grinberg L, Abrahamov A, Olivieri NF, Rachmilewitz EA, Hebbel RP, Blood 1995 86 2008 13 7655028
69. Deferiprone therapy in homozygous human beta-thalassemia removes erythrocyte membrane free iron and reduces KCl cotransport activity. De Franceschi L, Shalev O, Piga A, Collell M, Olivieri O, Corrocher R, Hebbel RP, Brugnara C, J Lab Clin Med 1999 133 64 9 10.1053/lc.1999.v133.a94241 10385483 (Pubitemid 29032418)
70. Deferiprone chelation therapy for thalassemia major. Galanello R, Campus S, Acta Haematol 2009 122 155 64 10.1159/000243800 19907153
71. Continued improvement in myocardial T2* over 2 years of deferasirox therapy in beta-thalassemia major patients with cardiac iron overload. Pennell DJ, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A, Haematologica 2011 96 48 54 10.3324/haematol.2010.031468 21071497
72. Continued improvement and normalization of myocardial T2* in patients with thalassemia major treated with Deferasirox (Exjade) for up to 3 years. Pennell D, Porter JB, Cappellini MD, Chan LL, El-Beshlawy A, Aydinok Y, Ibrahim H, Li CK, Viprakasit V, Elalfy MS, Kattamis A, Smith G, Habr D, Domokos G, Roubert B, Taher A, Blood 2010 116 bstract 4276
73. The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores. Wood JC, Kang BP, Thompson A, Giardina P, Harmatz P, Glynos T, Paley C, Coates TD, Blood 2010 116 537 43 10.1182/blood-2009-11-250308 20421452
74. Follow-up report on the 2-year cardiac data from a deferasirox monotherapy trial. Wood JC, Glynos T, Thompson A, Giardina P, Harmatz P, Kang BP, Paley C, Coates TD, Am J Hematol 2010 85 818 9 10.1002/ajh.21830 20799360
75. Iron chelators induce apoptosis in proliferating cells. Hileti D, Panayiotidis P, Hoffbrand AV, Br J Haematol 1995 89 181 7 7833261
76. Involvement of p38 MAP kinase during iron chelator-mediated apoptotic cell death. Kim BS, Yoon KH, Oh HM, Choi EY, Kim SW, Han WC, Kim EA, Choi SC, Kim TH, Yun KJ, Kim EC, Lyou JH, Nah YH, Chung HT, Cha YN, Jun CD, Cell Immunol 2002 220 96 106 10.1016/S0008-8749(03)00031-5 12657244 (Pubitemid 36349061)
77. Downregulation of p38 kinase pathway by cAMP response element-binding protein protects HL-60 cells from iron chelator-induced apoptosis. Choi SC, Kim BS, Song MY, Choi EY, Oh HM, Lyou JH, Han WC, Moon HB, Kim TH, Oh JM, Chung HT, Jun CD, Free Radic Biol Med 2003 35 1171 84 10.1016/S0891-5849(03)00503-3 14607516 (Pubitemid 37357242)
78. Deferasirox decreases age-associated iron accumulation in the aging F344XBN rat heart and liver. Arvapalli RK, Paturi S, Laurino JP, Katta A, Kakarla SK, Gadde MK, Wu M, Rice KM, Walker EM, Wehner P, Blough ER, Cardiovasc Toxicol 2010 10 108 16 10.1007/s12012-010-9068-9 20229123
79. Ion redistribution as a therapeutic strategy for treating diseases of localized iron accumulation. Kakhlon O, Breuer W, Munnich A, Cabantchik ZI, Can Physiol Pharmacol 2010 88 187 96 10.1139/Y09-128
80. Rescuing iron-overloaded macrophages by conservative relocation of the accumulated metal. Sohn YS, Mitterstiller AM, Breuer W, Weiss G, Cabantchik ZI, Br J Pharmacol 2011 164 406 18 21091647
81. Effects of deferasirox and deferiprone on cellular iron load in the human hepatoma cell line HepaRG. Gaboriau F, Leray AM, Ropert M, Gouffier L, Cannie I, Troadec MB, Loréal O, Brissot P, Lescoat G, Biometals 2010 23 231 45 10.1007/s10534-009-9281-9 19997770
82. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies. Voskaridou E, Christoulas D, Terpos E, Br J Haematol 2011 154 654 6 10.1111/j.1365-2141.2011.08626.x 21615376